In particular, for miR-125a, we selected Lin28b, MMP-11, SIRT-7, and Zbtb7a, well established targets with pivotal roles in HCC [25,27,29,30]; for let-7e, we selected Cyclin D1 (CCND1) and D2 (CCND2), validated targets in mouse hepatoblasts, but with conserved targeted sequence in humans, and HMGA2 and CDC25B recently validated in HCC [34,35]. The gene discussed is SIRT7; the disease is hepatocellular carcinoma.